---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-26-000002"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:02:15.854367+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q4 rev $875M (+17% Y/Y); GAAP net loss $47M on ROCTAVIAN withdrawal; Amicus deal on track

## Summary
- Q4 total revenues $875M (+17% Y/Y); full-year $3.22B (+13% Y/Y).
- Q4 GAAP net loss of $47M vs $125M income prior year; Non-GAAP income $89M vs $180M.
- ROCTAVIAN withdrawal triggered ~$240M Q4 charges ($119M inventory write-off, $118M asset impairments).
- VOXZOGO FY revenue $927M (+26% Y/Y); PALYNZIQ $433M (+22% Y/Y).
- 2026 guidance provided (ex-Amicus); Amicus acquisition expected to close in Q2'26.

## SEC filing metadata
- accession: 0001048477-26-000002
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/0001048477-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000002/bmrn-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-26-000002
- JSON: https://secwatch.observer/filing/0001048477-26-000002.json
- Plain text: https://secwatch.observer/filing/0001048477-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.